APA (7th ed.) Citation

C, S., I, G., N, N., A, L., S, C., I, M., . . . AM, R. (2025). Effectiveness of long-acting monoclonal antibodies against laboratory-confirmed RSV in children aged < 24 months and hospitalised for severe acute respiratory infection, European pilot study, 2024 to 2025. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 30(45), . https://doi.org/10.2807/1560-7917.ES.2025.30.45.2500816

Chicago Style (17th ed.) Citation

C, Savulescu, et al. "Effectiveness of Long-acting Monoclonal Antibodies Against Laboratory-confirmed RSV in Children Aged < 24 months and Hospitalised for Severe Acute Respiratory Infection, European Pilot Study, 2024 to 2025." Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin 30, no. 45 (2025). https://doi.org/10.2807/1560-7917.ES.2025.30.45.2500816.

MLA (9th ed.) Citation

C, Savulescu, et al. "Effectiveness of Long-acting Monoclonal Antibodies Against Laboratory-confirmed RSV in Children Aged < 24 months and Hospitalised for Severe Acute Respiratory Infection, European Pilot Study, 2024 to 2025." Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin, vol. 30, no. 45, 2025, https://doi.org/10.2807/1560-7917.ES.2025.30.45.2500816.